Replies to post #1575 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

If the DOJ forced Teva to divest branded Copaxone to consummate the deal, there would be no shortage of bidders.

But such bids would be based on a generic-drug valuation model, rather than a branded-drug model, for the reasons mentioned earlier in this thread. Nobody would step in to offer a branded-drug valuation, and hence Teva would be crazy to divest branded Copaxone in such a transaction.